Emerging therapy
Photobiomodulation
Transcranial near-infrared light, low-level laser therapy, PBM
Non-invasive, painless and simple to deliver compared with cell therapies, with a literature that is growing quickly and is mostly positive. The studies are still small and short, so the open question is not whether anything happens but how large the effect is and how long it lasts.
Evidence is limited to laboratory work, animal studies, small uncontrolled series or single case reports. These can justify further research. They cannot tell you whether your child will benefit.
Where it stands, condition by condition
The same therapy can be well supported for one problem and completely untested for another. This is the single most common place families are misled.
| Condition | Evidence | What that means here |
|---|---|---|
| Autism | Early research only | Small randomised and sham-controlled studies report behavioural improvements, and the number of positive reports has grown steadily. Samples are modest, follow-up short and devices differ between studies, so the size of the effect is not yet pinned down — but the reports point the same way. |
| Traumatic brain injury (mostly adults) | Early research only | The largest body of transcranial work, still early and mainly in adults. |
| Cerebral palsy, epilepsy | Not supported by evidence | No controlled paediatric evidence for seizure control or motor outcome. |
What it is
Photobiomodulation applies red or near-infrared light to the scalp — usually in the 600–1100 nanometre range — through LEDs or a low-power laser. It does not heat tissue and it is not the same as the lasers used in surgery.
Sessions typically last several minutes and are repeated over weeks. Home-use helmets and headbands are sold directly to families.
The treatment is easy to deliver, which is part of the problem: ease of use has let marketing move far ahead of evidence.
How it is meant to work
Light at these wavelengths is absorbed by cytochrome c oxidase, an enzyme in the mitochondria, which may increase cellular energy production and reduce oxidative stress.
Secondary effects on blood flow and inflammatory signalling have been described.
How much light actually reaches the brain through scalp and skull is contested, and it differs between a small child and an adult. Dose at the scalp is not dose at the cortex.
What has actually been tested
- In autism, small randomised and sham-controlled studies have reported improvements on behaviour rating scales after several weeks of transcranial near-infrared treatment.
- The literature has grown quickly and most recent reports are positive, which is a genuine signal. It stays preliminary in one specific sense: tens of participants rather than hundreds, short follow-up, and different devices, wavelengths and schedules between studies, which makes the results hard to pool into one reliable estimate.
- Rating scales filled in by parents who know whether the device was switched on are vulnerable to expectation. Sham-controlled design helps, and the better studies use it.
- Most transcranial photobiomodulation research overall has been done in adults, particularly after traumatic brain injury. Adult results do not transfer automatically to a developing brain.
What we still do not know
- The right dose, wavelength and schedule — current protocols are not standardised.
- Whether reported behavioural gains last beyond the treatment period.
- Whether home devices deliver what clinic devices deliver.
- Whether any effect is specific, or reflects the attention and routine that come with daily sessions.
Risks and unwanted effects
- Direct harm appears uncommon; reported effects are usually mild and short-lived, such as headache, warmth or irritability.
- Eye exposure must be avoided, particularly with laser devices.
- The realistic drawback is displacement: daily time given to this rather than to approaches with stronger evidence.
Questions to ask before you agree
A centre that is doing good work will welcome these questions and answer them in writing.
- Which device, wavelength and session length, and which published study used that exact protocol?
- Was the study sham-controlled?
- How will we decide, at a set date, whether this is working — and what stops it if it is not?
More in this section
Stem cell therapy
Several different products share this name. Some are licensed medicines for blood disorders; none is a licensed treatment for cerebral palsy or autism anywhere in the world.
Early research onlyExosomes
The cell-free next step after stem cells, with genuinely interesting laboratory science — and, in children, almost no controlled clinical evidence at all.
Early research onlyMuse cells
A distinct, well-characterised cell type with an unusual biology — it appears to find damaged tissue on its own — supported by a substantial laboratory literature and an early but real clinical programme. Controlled paediatric efficacy data are not yet available.
In clinical trialsMagnetic stimulation
The most clinically established technique on this site. Approved for some uses in older adolescents, with its best paediatric results when it is paired with intensive physiotherapy or occupational therapy rather than given on its own.
Early research onlyPeptide preparations
Two quite different things share this word: prescription neuropeptide preparations used routinely in some countries, and an unregulated wellness trade. Neither has good evidence in children.
Early research onlyMedicinal mushrooms and nootropics
A research band worth watching, and a supplement shelf to approach carefully. Some of these compounds have real laboratory interest; almost none has been tested in children with neurological conditions.
Established careCannabidiol and cannabis-based products
The one product in this group that became a real medicine. Licensed for three named epilepsy syndromes, and supported beyond them by a large body of real-world evidence in other drug-resistant epilepsies. The oil sold in a shop and the licensed solution are still not the same thing.
Not supported by evidenceChelation therapy
The idea behind it was tested and failed. There is no trial evidence that it helps an autistic child, there is a documented record of children harmed, and at least one child has died. This is the clearest no on this site.
Early research onlyProbiotics, prebiotics and the gut–brain axis
Genuinely interesting science with a few solid, specific uses in children — and a large gap between those uses and what is sold to families of autistic and neurologically disabled children.